[HTML][HTML] Phase I clinical trial of iv ascorbic acid in advanced malignancy
LJ Hoffer, M Levine, S Assouline, D Melnychuk… - Annals of …, 2008 - Elsevier
Annals of Oncology, 2008•Elsevier
Background Ascorbic acid is a widely used and controversial alternative cancer treatment. In
millimolar concentrations, it is selectively cytotoxic to many cancer cell lines and has in vivo
anticancer activity when administered alone or together with other agents. We carried out a
dose-finding phase I and pharmacokinetic study of iv ascorbic acid in patients with
advanced malignancies. Patients and methods Patients with advanced cancer or
hematologic malignancy were assigned to sequential cohorts infused with 0.4, 0.6, 0.9 and …
millimolar concentrations, it is selectively cytotoxic to many cancer cell lines and has in vivo
anticancer activity when administered alone or together with other agents. We carried out a
dose-finding phase I and pharmacokinetic study of iv ascorbic acid in patients with
advanced malignancies. Patients and methods Patients with advanced cancer or
hematologic malignancy were assigned to sequential cohorts infused with 0.4, 0.6, 0.9 and …
Background
Ascorbic acid is a widely used and controversial alternative cancer treatment. In millimolar concentrations, it is selectively cytotoxic to many cancer cell lines and has in vivo anticancer activity when administered alone or together with other agents. We carried out a dose-finding phase I and pharmacokinetic study of i.v. ascorbic acid in patients with advanced malignancies.
Patients and methods
Patients with advanced cancer or hematologic malignancy were assigned to sequential cohorts infused with 0.4, 0.6, 0.9 and 1.5 g ascorbic acid/kg body weight three times weekly.
Results
Adverse events and toxicity were minimal at all dose levels. No patient had an objective anticancer response.
Conclusions
High-dose i.v. ascorbic acid was well tolerated but failed to demonstrate anticancer activity when administered to patients with previously treated advanced malignancies. The promise of this approach may lie in combination with cytotoxic or other redox-active molecules.
Elsevier